Efficacy Observation of Pegylated Interferonα-2a Combined with Adefovir in the Treatment of HBeAg Posi-tive Chronic Hepatitis B
10.6039/j.issn.1001-0408.2015.29.28
- VernacularTitle:聚乙二醇干扰素α-2a联合阿德福韦治疗HBeAg阳性慢性乙型肝炎的疗效观察
- Author:
Quanguo LI
;
Yunfeng ZHANG
- Publication Type:Journal Article
- Keywords:
Pegylated interferonα-2a;
Adefovir;
Drug combination;
Chronic hepatitis B;
HBsAg;
Positive
- From:
China Pharmacy
2015;(29):4112-4114
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy of pegylated interferon α-2a(Peg-INFα-2a)combined with adefovir (ADV)in the treatment of HBeAg-positive chronic hepatitis B (CHB). METHODS:An open randomized controlled clinical trial was performed. According to random number table,70 patients with HBeAg-positive chronic hepatitis B were divided into observa-tion group and control group,with 35 cases in each group. Observation group received Peg-INF α-2a combined with ADV,and control group was treated with Peg-INF α-2a only. Therapeutic efficacy and safety evaluation were evaluated after 24 and 48 weeks of treatment. RESULTS:After 24 weeks of treatment,ALT normalization rate of observation group and control group were 51.43%and 25.71%,and HBV-DNA negative rate of 2 groups were 68.57% and 37.14% respectively,with statistical significance (P<0.05). There was no statistical significance between HBsAg negative rate and HBeAg negative rate (P>0.05). After 48 weeks of treatment,ALT normalization rate of observation group and control group were 77.14% and 54.29%,and HBeAg negative rate 54.29% and 31.43%,and HBV-DNA negative rate 82.86% and 42.86% respectively,with statistical significance(P<0.05).There was no statistical significance in HBsAg negative rate and ADR (P>0.05). CONCLUSIONS:Peg-INFα-2a combined with ADV have good clinical efficacy in the treatment of HBeAg-positive CHB,and it is better than Peg-INFα-2a monotherapy and has less ADR.
